Welcome to our dedicated page for Chinook Therapeutics news (Ticker: KDNY), a resource for investors and traders seeking the latest updates and insights on Chinook Therapeutics stock.
Chinook Therapeutics, Inc. (NASDAQ: KDNY) is a clinical-stage biotechnology company focused on developing precision medicines specifically for kidney diseases. Kidney diseases pose a significant and growing health challenge globally, often requiring costly treatments like dialysis and transplantation. Chinook is at the forefront of addressing this need through advanced understanding of disease biology and cutting-edge translational platforms.
The company’s lead product candidates include atrasentan, a phase 3 endothelin receptor antagonist aimed at treating IgA nephropathy and proteinuric glomerular diseases, and zigakibart (BION-1301), an anti-APRIL monoclonal antibody undergoing a phase 1/2 trial for IgA nephropathy. Additionally, CHK-336, an oral small molecule LDHA inhibitor, is being developed for hyperoxalurias and other kidney stone disorders, currently in phase 1 trials.
Recent achievements highlight their commitment to innovation. Data from the phase 1 study of CHK-336 demonstrated hepatic LDH target engagement and decreased oxalate production, albeit with ongoing investigations into observed serious adverse events. The initiation of the phase 3 BEYOND study for zigakibart marks another milestone in providing new treatment options for patients with IgAN, reinforcing the potential of their therapies to modify disease progression.
Chinook’s approach leverages data from comprehensive kidney single-cell RNA sequencing and large chronic kidney disease (CKD) patient cohorts to identify key therapeutic targets. This strategy enables them to build a robust pipeline of precision medicines for rare and severe kidney diseases. Their research benefits from rich clinical data and patient samples, providing insights that drive the development of their innovative drug candidates.
Financially, Chinook remains focused on advancing its clinical programs while exploring strategic collaborations and partnerships to bolster its development efforts. Their strong scientific foundation and strategic focus positions them as a leader in the field of kidney disease therapeutics.
For more detailed updates and ongoing news, visit their official website at www.chinooktx.com.
Chinook Therapeutics, Inc. (NASDAQ: KDNY) will present significant data at the 59th ERA Congress in Paris from May 19-22, 2022. Highlighted presentations include atrasentan for IgA nephropathy and updated data from the BION-1301 trial. The company will also discuss the mechanisms behind mesangial cell injury and chronic kidney disease classification. An investor conference call is scheduled for May 20, 2022, to review these abstracts, featuring experts from leading institutions.
Chinook Therapeutics, a biopharmaceutical firm focused on kidney diseases, will present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022, at 10:00 am ET in Toronto. The event will include 1x1 meetings with management. Interested investors can access a live webcast and archived recordings through Chinook’s official website, available for replay for 90 days following the event. Chinook is developing precision medicines, including atrasentan for IgA nephropathy and other chronic kidney disorders, as part of its commitment to advancing treatment options.
Chinook Therapeutics (NASDAQ: KDNY) has initiated dosing in a Phase 1 clinical trial for CHK-336, an oral small molecule LDHA inhibitor targeting hyperoxaluria. This marks Chinook's first internally discovered program. The trial aims to assess safety, tolerability, and pharmacokinetics in up to 104 healthy volunteers. Preclinical results indicate CHK-336 significantly reduces urinary oxalate excretion in mouse models, showcasing its potential for treating patients with primary and secondary hyperoxaluria. Successful development could lead to a first-in-class therapy.
Chinook Therapeutics, Inc. (Nasdaq: KDNY) announced that CEO Eric Dobmeier will present at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 3:00 PM ET. The event will include 1x1 meetings with management. Interested parties can access the live webcast and archived recordings on Chinook's Investors website for 90 days after the event. Chinook specializes in precision medicines for kidney diseases, with ongoing clinical trials for products like atrasentan and BION-1301.
Chinook Therapeutics, Inc. (Nasdaq: KDNY) has partnered with the IgA Nephropathy Foundation and Komodo Health to enhance awareness of IgA nephropathy, a severe kidney disease. This initiative aims to engage healthcare providers and improve early diagnosis and treatment options through strategic outreach and the application of data insights from Komodo's software. The collaboration seeks to empower both patients and providers with resources to better navigate the challenges associated with IgA nephropathy, addressing the significant unmet needs in the patient community.
Chinook Therapeutics (NASDAQ: KDNY) has appointed Dr. Mahesh Krishnan to its Board of Directors. Dr. Krishnan, with over 20 years in nephrology, is currently a group vice president at DaVita Inc. His extensive expertise will contribute significantly to Chinook's development of precision medicines for kidney diseases. This leadership change aims to bolster the company’s diverse pipeline and support its late-stage clinical programs. The company is focused on treatments for severe chronic kidney diseases, including IgA nephropathy.
Chinook Therapeutics (Nasdaq: KDNY) reported a productive 2021, marked by advancements in clinical trials for atrasentan and BION-1301. The company initiated the phase 3 ALIGN and phase 2 AFFINITY trials for atrasentan and presented promising data for BION-1301. Financially, Chinook reported a net income of $7.5 million for Q4 2021, a significant turnaround from a net loss in the previous year. Total revenue increased by $50.4 million for Q4 2021. By year-end, cash and marketable securities reached $355.1 million, up from $250.4 million in 2020, bolstered by a public offering.
Chinook Therapeutics, Inc. (NASDAQ: KDNY), focused on precision medicines for kidney diseases, will participate in a virtual fireside chat and 1x1 meetings at Oppenheimer’s 32nd Annual Healthcare Conference on March 15, 2022, at 10:40 am ET. The event will be accessible via a live webcast, with archived recordings available for 90 days on the company’s website. Chinook's lead program is atrasentan, targeting IgA nephropathy, alongside other promising drug candidates for severe chronic kidney disorders.
Chinook Therapeutics, focused on precision medicines for kidney diseases, announced its participation at the 4th Annual Chronic Kidney Disease Drug Development Summit in Boston from March 1-3, 2022. They will host a panel discussing drug development challenges and present on two key clinical studies: the AFFINITY Phase 2 trial for atrasentan targeting multiple proteinuric glomerular diseases and a study on BION-1301 for IgA nephropathy. Notable participants include Chief Scientific Officer Andrew King and Senior Medical Director Marianne Camargo.
Chinook Therapeutics (NASDAQ: KDNY) will present several abstracts at the ISN World Congress of Nephrology 2022 from February 24 to 27, 2022. Key presentations include data from:
- Atrasentan: The ALIGN Study (Phase 3 on IgA Nephropathy)
- Atrasentan: The AFFINITY Study (Proteinuric Glomerular Diseases)
- BION-1301: Phase 1/2 Trial Results on IgA Nephropathy
- BION-1301: ADU-CL-19 Trial on Safety and Pharmacodynamics
Chinook focuses on precision treatments for severe chronic kidney diseases.
FAQ
What is the market cap of Chinook Therapeutics (KDNY)?
What is Chinook Therapeutics, Inc.?
What are the main products of Chinook Therapeutics?
What recent achievements has Chinook Therapeutics made?
What is the BEYOND study?
How does Chinook Therapeutics develop its medicines?
Where can I find more information about Chinook Therapeutics?
What are the goals of Chinook Therapeutics' clinical programs?
What are the potential benefits of Chinook's drug candidates?
How does Chinook Therapeutics contribute to kidney disease treatment?
What is the significance of CHK-336?
